Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Chimeric Therapeutics Ltd. ( (AU:CHM) ) just unveiled an announcement.
Chimeric Therapeutics has announced the advancement of its CHM CDH17 clinical trial to Dose Level 2, following successful completion of Dose Level 1 with no safety concerns. The trial, which involves administering 150 million CHM CDH17 CAR-T+ cells, aims to determine the recommended Phase 2 dose and evaluate safety and response rates in patients with advanced colorectal, gastric, and intestinal neuroendocrine tumors. The positive safety profile and early signs of clinical activity, such as stable disease in some patients, highlight the potential of CHM CDH17 as a transformative cancer treatment.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics is a clinical stage cell therapy company focused on developing innovative cell therapies for cancer treatment. The company has a diversified portfolio that includes autologous CAR T cell therapies and allogeneic NK cell therapies, with assets being developed across multiple oncology areas. Chimeric’s CHM CDH17 is a first-in-class, third-generation CAR T therapy targeting CDH17, a cancer biomarker, and is currently in a phase 1/2 clinical trial for gastrointestinal and neuroendocrine tumors.
Technical Sentiment Signal: Sell
Current Market Cap: A$14.81M
For an in-depth examination of CHM stock, go to TipRanks’ Stock Analysis page.